Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 730460 in Healthy Subjects
NCT03483077Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 730460 in psoriasis (7 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants With Drug-related Adverse Events up to 13 days. Started Oct 2018; status: terminated.
02
Drugs
BI 730460
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03483077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483077.